‘Hard Truths’ For Sentinel: US FDA Scales Back Active Surveillance Ambitions

 
• By Grace Moser
  
The FDA is limiting Sentinel development due to budget constraints. (Shutterstock)

More from Post-Marketing Regulation & Studies

More from R&D